meRfi®-GM
Porphyromonas gingivalis
Welcome to meRfi-GM!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Navigation
Contents
GenBankAC: AP009380
Immunosuppressive properties of the oral anaerobic bacterium Porphyromonas gingivalis are revealed, highlighting effects of the bacterium that facilitate oral cancer progression. The data suggest that P. gingivalis, and/or signaling it mediates, can be targeted to improve immunotherapy efficacy
Porphyromonas gingivalis belongs to the species in the healthy human gut- the abundance is low: about 0.01% of all species in the healthy human gut
see also:
[Immune Checkpoint Inhibitors (ICIs) Therapy (to improve) & Drugs/Treatments](bra…
References (Sources)
- Baseline human gut microbiota profile in healthy people and standard reporting template
- P. gingivalis in Periodontal Disease and Atherosclerosis - Scenes of Action for Antimicrobial Peptides and Complement
- P. gingivalis Infection Upregulates PD-L1 Expression on Dendritic Cells, Suppresses CD8þ T-cell Responses, and Aggravates Oral Cancer
- Porphyromonas gingivalis infection accelerates the progression of atherosclerosis in a heterozygous apolipoprotein E-deficient murine model
- Porphyromonas gingivalis-induced platelet aggregation in plasma depends on Hgp44 adhesion but not Rgp proteinase